These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 26657098)

  • 21. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
    Last AR; Ference JD; Menzel ER
    Am Fam Physician; 2017 Jan; 95(2):78-87. PubMed ID: 28084704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [2016 European Society of Cardiology guidelines for the management of dyslipidemias].
    Ferrières J
    Presse Med; 2017; 46(7-8 Pt 1):688-696. PubMed ID: 28502376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins and the cholesterol mortality paradox.
    Nunes JP
    Scott Med J; 2017 Feb; 62(1):19-23. PubMed ID: 27889702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Importance of dyslipidaemia in cardiovascular disease: a point of view].
    Ascaso JF; Carmena R
    Clin Investig Arterioscler; 2015; 27(6):301-8. PubMed ID: 26363575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCSK9 inhibitors--past, present and future.
    Reiner Ž
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1517-21. PubMed ID: 26329686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on statins and other lipid-lowering drugs.
    Miller CA
    Geriatr Nurs; 2001; 22(5):276-7. PubMed ID: 11606910
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapeutic strategies. Evolution and current status of the European Guidelines on Cardiovascular disease prevention].
    Guijarro C; García-Díaz Jde D
    Clin Investig Arterioscler; 2013; 25(2):92-7. PubMed ID: 23769961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Lipid-lowering therapy in Europe and the United States - treat to target or fire and forget?].
    Pfetsch V; Sanin V; Koenig W
    Dtsch Med Wochenschr; 2016 Jun; 141(12):857-62. PubMed ID: 27305301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-modifying drugs.
    Simons LA; Sullivan DR
    Med J Aust; 2005 Mar; 182(6):286-9. PubMed ID: 15777144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New guidelines on treatment of blood cholesterol: too much of a good thing?].
    Lippi G; Mattiuzzi C
    Recenti Prog Med; 2014 Sep; 105(9):317-21. PubMed ID: 25229759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 36. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Lowering cholesterol: how low is low enough?].
    Czuriga I; Edes I
    Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Masana L; Pedro-Botet J; Civeira F
    Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
    [No Abstract]   [Full Text] [Related]  

  • 39. [Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective].
    Fruchart JC
    Presse Med; 2002 Sep; 31(30):1428-33. PubMed ID: 12378980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.
    März W; Scharnagl H; Gouni-Berthold I; Silbernagel G; Dressel A; Grammer TB; Landmesser U; Dieplinger H; Windler E; Laufs U
    Am J Cardiovasc Drugs; 2016 Oct; 16(5):323-36. PubMed ID: 27430233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.